分组1 - Entrada Therapeutics reported a quarterly loss of $0.42 per share, which was better than the Zacks Consensus Estimate of a loss of $0.78, representing an earnings surprise of 46.15% [1] - The company posted revenues of $20.56 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 111.61%, although this is a decline from $59.12 million in the same quarter last year [2] - Entrada Therapeutics has surpassed consensus EPS estimates for the last four quarters and has also topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed, losing about 52.8% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.81 on revenues of $9.22 million, and for the current fiscal year, it is -$3.32 on revenues of $35.86 million [7] - The Medical - Biomedical and Genetics industry, to which Entrada Therapeutics belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable industry outlook [8]
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates